Actavis to acquire Alpharma's Human Generics business
Actavis becomes one of top 5 global generics players
Advertisement
Actavis Group announced that it has agreed to acquire the human generics business of the US listed pharmaceutical company, Alpharma Inc., for a total consideration of US$810 million in cash. The deal brings together two premier generic pharmaceutical businesses with complementary strengths in Europe and the US and represents a significant milestone in Actavis' goal to become one of the leading global companies within the sector.
The combination of Actavis' brand and geographic coverage in Europe and the US with Alpharma's attractive position in the US market and own label sales in key European markets is expected to generate substantial opportunities to drive revenue growth, provide significant synergies and create shareholder value for the enlarged Group. Following the acquisition Actavis will be among the five largest companies in generic pharmaceuticals worldwide, in terms of revenue.
The enlarged Group will have one of the broadest portfolios in the generics sector with over 600 products on the market. Alpharma's strong liquid product portfolio complements Actavis' strengths in oral solid-dose products and there is minimal overlap in both pipeline and portfolios for the US market.
Most read news
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany - "This new facility will allow us to better serve our customers and explore new chromatography techniques and applications"
Ajinomoto to Invest a Total of 15 Billion to Expand Production of Feed Grade Amino Acids and Umami Seasonings
New 'self-exploding' microcapsules could take sting out of drug delivery

Asphaltene analysis takes a giant step - Rice researchers develop accurate measure of aggregating particles that block oil production lines

Hybrid electro-biosystem upcycles carbon dioxide into energy-rich long-chain compounds - Upcycling CO₂ via electrochemical and metabolic engineering
Tiny Tubes for Biotransport - Researchers clarify cellular uptake mechanisms for carbon nanotubes
Albemarle Announces Custom Manufacturing Agreement With ExxonMobil Chemical - Agreement provides 15,000 metric tons per year of high viscosity polyalphaolefins production

Water-Soluble Warped Nanographene - Synthesis of a water-soluble warped nanographene and its application for photo-induced cell death
Great interest in million-euro idea - Covestro funds best employee start-up team

New insight into thermoelectric materials may boost green technologies
ALTANA: Research and development investments increased significantly again - 2015 Results: ALTANA’s Sales Increase by 5 Percent
